Navigation Links
Novel Catheter Technique Successfully Patches Holes in the Heart

A novel catheter technique for patching holes in the heart may make it possible for many patients to avoid surgery altogether and others to regain enough strength to safely undergo surgical repair at a later date, according to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions, May 912, 2007, in Orlando, FL.

The patch successfully closed ventricular septal defects(VSDs)or ruptures in the wall between the right and left ventriclesin nearly all patients, allowing blood to circulate normally again and relieving fluid back-up in the lungs. After recovery, patients were able to return to active lives.

"Patients with acute VSDs may be critically ill with heart failure and perhaps be in cardiogenic shock," said Matthew W. Martinez, M.D., a cardiology fellow at the Mayo Clinic in Rochester, MN. "This procedure offers an alternative for patients who are too sick to undergo emergency heart surgery or simply don't want surgery."

To track the long-term effectiveness of the catheter procedure, Dr. Martinez and his colleagues reviewed the medical records of 10 patients treated with the VSD patch between 1995 and 2005. Of these, 5 patients experienced rupture of the ventricular wall, or septum, as a result of a heart attack. In the other 5 patients, the VSD was an unintended consequence of a previous heart surgery.

In all cases, the VSD allowed a portion of the blood in the left ventricle to shoot backward into the right ventricle with each heart beat, rather than being circulated to the rest of the body. As a result, patients were experiencing such severe heart failure they were short of breath at rest or with minimal activity, and were judged to have New York Heart Association class 3 and 4 heart failure.

A variety of patches were used in the study, but all were some form of AMPLATZER Occluder (AGA Medical Corp., Plymouth, MN). The VSD patch is composed of two discs connected by a thick shaft. The discs are made of flexible nitinol metal and covered in polyester fabric that encourages heart tissue to grow over the discs, completely covering them during healing.

Before implantation, the flexible double-disc patch is pulled into a catheter, collapsing and compressing it lengthwise. It is then threaded through a vein into the right ventricle and across the rupture into the left ventricle. The patch is pushed partially out of its catheter sheath until the first disc pops open. The catheter is then withdrawn back into the right ventricle, with the first disc positioned against the left ventricular wall and the connecting shaft filling the hole created by the rupture. From inside the right ventricle, the patch is pushed forward again, releasing the second disc, which covers the rupture on the right side of the heart.

Implantation of the VSD occluder was performed by Donald J. Hagler, M.D., FSCAI, a professor of pediatrics in the Divisions of Pediatric Cardiology and Cardiovascular Diseases at the Mayo Clinic. The procedure was successful in all patients, without complications. One patient died 5 days later of illness unrelated to the VSD patch. In 2 patients, the rupture didn't fully heal, causing damage to blood cells as they jetted through the narrow opening. A third patient developed a bacterial infection that started several months after device implantation. The patch was removed and all 3 patients had successful surgery to repair the rupture.

Even in such cases, the VSD patch serves its purpose by allowing patients to regain enough strength to withstand surgery, Dr. Martinez said. "Surgery is the long-term answer for some patients," he said. "In such cases, the VSD occluder successfully bridges the patients to surgery."

After a follow-up that averaged more than 1 year, patients were feeling markedly better and were much more active, even able to cl imb a flight of stairs before becoming short of breath. All patients were ranked in New York Heart Association class 2 or better.


'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: